Neurocrine Biosciences, Inc.

Good day everyone and welcome to today's Neurocrine Biosciences reports second quarter results. This time all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session. Please note today's call may be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Please go ahead.

Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2022 earnings call. With me are Kevin Gorman, our Chief Executive Officer, Matt Abernethy, our Chief Financial Officer, Eiry Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. In our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we'll head into Q&A where we'll try to get to everyone's questions. And now I'll turn the call over to Kevin Gorman.

Thank you, Todd, and good afternoon. As Todd said, we're going to all keep our opening remarks short to give us enough time for your questions. Ingresa had a very good Q2, and coupled with our outperformance in Q1, we have had an excellent first half of the year. Eric is going to take you through the quarter in a bit more detail in just a moment. Now, in addition, I'm very pleased to say we continue to grow our pipeline, adding two new compounds with validated mechanisms of action in psychiatry, and Eiry will talk a bit about those two. Now, as you've seen in our press release, Our signal-seeking essential tremor study did not yield a strong enough data set to warrant any further development of this compound in ET at this time. While disappointing, we have a rich and diversified portfolio, and these resources will be rapidly redeployed. Now, finally, I'd like to say that I'm very pleased with the overall performance of the company thus far this year. We, and here I mean the larger we, all of business and society, are dealing with the transition out of a pandemic and into an endemic Thank you for joining us. I'd like to turn it over to Matt now, please.